Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 22, 2025Frontiers in OncologyOpen Access

CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJing ShenSecond Military Medical UniversityJZJingyi ZhangSichuan UniversityZZZhengyu ZhuSecond Hospital of Shandong University

Discussion

Loading...

Member takes

Implication

Systematic review reveals overall response rates of 54.5% in patients with large B-cell lymphoma, suggesting bispecific antibodies may boost CAR-T therapy outcomes.

Key Points

  • CD20×CD3 bispecific antibodies show significant efficacy in patients with relapsed large B-cell lymphoma.
  • Overall response rate for pooled bispecific antibody analysis reached 54.5%, and complete response rate was 35.6%.
  • Analysis includes nine trials with 350 participants, assessing various response outcomes, including overall survival.
  • Further prospective trials are needed to validate the effectiveness and optimal sequencing of bispecific antibodies with CAR-T therapy.

Cite This Study

Shen et al. (2025) studied this question.

synapsesocial.com/papers/68af55ccad7bf08b1eadbf7chttps://doi.org/10.3389/fonc.2025.1641769
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The development of software to support multiple systematic review types2018 · 986 citations
  2. 2Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study2024 · 32 citations
  3. 3Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial2023 · 99 citations
  4. 4Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas2024 · 14 citations
  5. 5Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy2022 · 49 citations